Some of Friday's midday movers:
The market may have rallied, but "Mad Money" host Jim Cramer thinks that’s just the beginning of Yellen’s impact.
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Drug giant Sanofi is juggling legal and regulatory issues surrounding three cases involving alleged payments or inducements to medical providers.
CNBC's Meg Tirrell provides insight to a lawsuit regarding a scheme at Sanofi involving its diabetes drug.
A lawsuit accuses drug maker Sanofi and top executives, including its ousted CEO, of a million-dollar kickback scheme to promote diabetes drug sales.
GSK will ax hundreds of U.S. jobs in its biggest market as the drugmaker starts implementing a major cost-saving program.
Pfizer's attempt to take over AstraZeneca through a $110 billion bid would have run aground on changes to U.S. tax laws, even if the companies had reached a deal.
There are few new cancer drugs to treat kids, and not much research is being done.
European shares closed lower on Thursday as investors reacted to worse-than-expected data from the euro zone.
After drug company Sanofi removed CEO Chris Viehbacher, investors question the future of the company's growth and future.
Some of Tuesday's midday movers:
European shares closed marginally higher on Wednesday, after a bumpy day of trading, as investors looked ahead to the Fed's policy statement.
Editor of SCRIP Intelligence, Eleanor Malone, says it's a "shocking move" for Sanofi to sack its CEO over what she described as "relatively small misdemeanours."
Insight to why Sanofi's CEO Chris Viehbacher could have been ousted at the company, with CNBC's Meg Tirrell.
CNBC's David Faber reports Sanofi CEO Christopher Viehbacher has been fired by the French drug maker's board of directors.
Some of the names on the move ahead of the open.
Sanofi shares tumbled up to 6.2 percent on Wednesday after the French drugmaker's board said it was ousting chief executive, Chris Viehbacher.
Total warned that sliding oil prices had hit its third-quarter results and could weigh for the rest of 2014.
European stocks ended the day firmly in positive territory on Tuesday, as investors prepared for a key monetary policy decision from the U.S.